Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership SOMERSET, N.J. & COPENHAGEN, Denmark, December 18, 2024 ...

(RTTNews) - Wednesday, Novo Holdings A/S completed the acquisition of Catalent, Inc. (CTLT), a global contract development and manufacturing organization, in an all-cash transaction worth ...

Dec 18 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, on Wednesday sealed its $16.5 billion deal for Catalent (CTLT.N), opens new tab ...

Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership Catalent, Inc. (“Catalent”), a leader in ...

In recent trading, shares of Catalent Inc (Symbol: CTLT) have crossed above the average analyst 12-month target price of $63.42, changing hands for $63.48/share. When a stock reaches the target an ...

Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership Catalent, Inc. ("Catalent"), a leader in enabling the ...

(RTTNews) - Catalent Inc. (CTLT) and Novo Holdings A/S announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to ...

SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo ...

Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the Federal Trade Commission decided not to challenge the deal. It’s expected to ...

Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory ...

Novo Holdings, the parent company of Novo Nordisk, can proceed with its planned $16.5 billion acquisition of Catalent, a leading contract drug manufacturer, after U.S. regulators declined to ...